UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported) November 1, 2018

GRAPHIC


Cross Country Healthcare, Inc.
 (Exact name of registrant as specified in its charter)


Delaware 0-33169 13-4066229

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

5201 Congress Avenue, Suite 100B, Boca Raton, FL 33487
(Address of Principal Executive Office) (Zip Code)

(561) 998-2232
 (Registrant’s telephone number, including area code)

Not Applicable
 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Section 2 – Financial Information

Item 2.02     Results of Operations and Financial Condition

(a)  On November 1, 2018, Cross Country Healthcare, Inc. (“the Company”) issued a press release announcing results for the quarter ended September 30, 2018, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. This information is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

Section 7 – Regulation FD

Item 7.01     Regulation FD Disclosure

Incorporated by reference is a press release issued by the Company on November 1, 2018, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

Section 9 – Financial Statements and Exhibits

Item 9.01     Financial Statements and Exhibits

(d) Exhibits

  Exhibit Description
 

99.1

Press Release issued by the Company on November 1, 2018


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CROSS COUNTRY HEALTHCARE, INC.
 
 

 

 

By:

/s/ Christopher R. Pizzi

Christopher R. Pizzi

Dated:

November 1, 2018

SVP & Chief Financial Officer

Exhibit 99.1

Cross Country Healthcare Announces Third Quarter 2018 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--November 1, 2018--Cross Country Healthcare, Inc. (the "Company") (Nasdaq: CCRN) today announced financial results for its third quarter ended September 30, 2018.

FINANCIAL HIGHLIGHTS:

Dollars are in thousands, except per share amounts

                        Q3 2018                

Variance

Q3 2018 vs

Q3 2017

                 

Variance

Q3 2018 vs

Q2 2018

 
                                 
Revenue                         $200,717                 (12)%                   (2)%  
 
Gross profit margin*                         25.7%                

(80) bps

                 

(50) bps

 
 
Net loss attributable to common shareholders                         $(441)                 (107)%                   (129)%  
 
Diluted EPS                         $(0.01)                 $(0.20)                   $(0.05)  
 
Adjusted EBITDA*                         $8,112                 (41)%                   (7)%  
 
Adjusted EPS*                         $0.02                 $(0.21)                   $(0.03)  
 
Cash flows from operations                         $3,818                 20%                   (18)%  
 

* Refer to accompanying tables and discussion of Non-GAAP financial measures below.

“Our results for the third quarter were in line with our expectations despite a further decline in premium rate business and higher than anticipated healthcare costs,” said William J. Grubbs, President and Chief Executive Officer. “We are encouraged by the significant recent increase in demand we are experiencing across many of our key customers and geographies especially in travel nurse, our largest service line. To capitalize on this favorable trend, we are making investments in producer headcount. Therefore, we are guiding to a sequentially flat Adjusted EBITDA, reflecting the investments and higher healthcare costs. The anticipated ramp from our recent MSP wins, investments, and recent productivity initiatives, along with favorable market conditions, position us well as we enter 2019.”

Third quarter consolidated revenue was $200.7 million, a decrease of 12% year-over-year and 2% sequentially. Consolidated gross profit margin was 25.7%, down 80 basis points year-over-year and 50 basis points sequentially. Net loss attributable to common shareholders was $0.4 million compared to net income of $6.7 million in the prior year and $1.5 million in the prior quarter. Diluted EPS was a loss of $0.01 per share compared to income of $0.19 per share in the prior year and $0.04 in the prior quarter. Adjusted EBITDA was $8.1 million or 4.0% of revenue, as compared with $13.8 million or 6.0% of revenue in the prior year, and $8.7 million or 4.3% of revenue in the prior quarter. Adjusted EPS was $0.02 in the current quarter as compared to income of $0.23 in the prior year and $0.05 in the prior quarter.


For the nine months ended September 30, 2018, consolidated revenue was $615.6 million, a decrease of 5% year-over-year, 10% excluding the impact of the Advantage acquisition. Consolidated gross profit margin was 25.8%, down 60 basis points year-over-year. Adjusted EBITDA was $25.2 million or 4.1% of revenue, as compared with $31.1 million or 4.8% of revenue in the prior year. Net income attributable to common shareholders was $2.7 million, or $0.08 per diluted share, compared to net income of $9.6 million, or $0.24 per diluted share, in the prior year. Adjusted EPS was $0.13 compared to $0.44 in the prior year.

Quarterly Business Segment Highlights

Nurse and Allied Staffing

Revenue from Nurse and Allied Staffing was $176.3 million, a decrease of 12% year-over-year and 2% sequentially. Contribution income in this segment was $16.5 million, down from $20.7 million in the prior year, and down sequentially from $16.9 million in the prior quarter. Average field FTEs decreased to 6,953 from 7,706 in the prior year and decreased from 7,143 in the prior quarter. Revenue per FTE per day was $276 compared to $283 in the prior year and $276 in the prior quarter.

Physician Staffing

Revenue from Physician Staffing was $21.2 million, a decrease of 15% year-over-year and 1% sequentially. Contribution income was $1.3 million, consistent with the prior year, and $1.4 million in the prior quarter. Total days filled were 13,375 as compared with 15,567 in the prior year and 13,751 in the prior quarter. Revenue per day filled was $1,582 as compared with $1,598 in the prior year and $1,551 in the prior quarter.

Other Human Capital Management Services

Revenue from Other Human Capital Management Services was $3.2 million, an increase of 3% year-over-year and a decrease of 18% sequentially. Segment contribution income was $0.1 million for the current quarter compared to breakeven in the prior year, and $0.3 million in the prior quarter.

Cash Flow and Balance Sheet Highlights

Cash flow from operations for the quarter was $3.8 million, compared to $3.2 million in the prior year. During the third quarter, the Company made principal payments of $6.3 million, including an optional prepayment of $5.0 million. Cash flow from operations was $21.8 million year-to-date September 30, 2018, compared to $28.7 million in the prior year-to-date period.


During the quarter, the Company also repurchased 32,983 shares of common stock for $0.3 million, at an average market price of $9.08 per share. Year-to-date repurchases totaled 432,439 shares of common stock for $5.0 million at an average market price of $11.54. As of September 30, 2018, the Company had 35.6 million shares outstanding. The Company has 510,004 shares remaining for repurchase under its current share repurchase program, subject to certain conditions in its credit agreement.

As of September 30, 2018, the Company had $28.1 million in cash and cash equivalents and a $91.3 million principal balance on our term loan. There were no amounts drawn on the Company's $115.0 million revolving credit facility and $20.6 million of letters of credit outstanding, leaving $94.4 million available for borrowing under the revolving credit facility as of September 30, 2018.

Outlook for Fourth Quarter 2018

The guidance below applies only to management’s expectations for the fourth quarter of 2018.

       

Q4 2018 Range

        Year-over-Year         Sequential
Change Change
 
Revenue $195 million - $205 million (11)% - (7)% (3)% - 2%
 
Gross profit margin 25.0% - 25.5% (150) - (100) bps (70) - (20) bps
 
Adjusted EBITDA $8 million - $9 million (35)% - (27)% (1)% - 11%
 
Adjusted EPS $0.01 - $0.03 $(0.16) - $(0.14) $(0.01) - $0.01
 

The estimates above are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions or other business combinations, any changes in debt structure, or any future share repurchases. See accompanying Non-GAAP financial measures and tables below.

INVITATION TO CONFERENCE CALL

The Company will hold its quarterly conference call on Thursday, November 1, 2018, at 5:00 P.M. Eastern Time to discuss its third quarter 2018 financial results. This call will be webcast live and can be accessed at the Company's website at www.crosscountryhealthcare.com or by dialing 800-857-6331 from anywhere in the U.S. or by dialing 517-623-4781 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from November 1st through November 15th at the Company's website and a replay of the conference call will be available by telephone by calling 800-944-9725 from anywhere in the U.S. or 402-220-3524 from non-U.S. locations - Passcode: 2018.


ABOUT CROSS COUNTRY HEALTHCARE

Cross Country Healthcare is a national leader in providing innovative healthcare workforce solutions and staffing services. Our solutions leverage our nearly 40 years of expertise and insight to assist clients in solving complex labor-related challenges while maintaining high quality outcomes. We are dedicated to recruiting and placing highly qualified healthcare professionals in virtually every specialty and area of expertise. Our diverse client base includes both clinical and nonclinical settings, servicing acute care hospitals, physician practice groups, outpatient and ambulatory-care centers, nursing facilities, both public schools and charter schools, rehabilitation and sports medicine clinics, government facilities, and homecare. Through our national staffing teams and network of 70 office locations, we are able to place clinicians on travel and per diem assignments, local short-term contracts and permanent positions. We are a market leader in providing flexible workforce management solutions, which include managed service programs (MSP), internal resource pool consulting and development, electronic medical record (EMR) transition staffing, recruitment process outsourcing, predictive modeling, and other outsourcing and consultative services. In addition, we provide both retained and contingent placement services for healthcare executives, physicians, and other healthcare professionals.

Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

NON-GAAP FINANCIAL MEASURES

This press release and accompanying financial statement tables reference non-GAAP financial measures. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned.]Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. Beginning with the third quarter of 2018, the Company modified its non-GAAP performance measures to exclude expenses related to the replacement of its legacy travel nurse front-end system. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.


FORWARD LOOKING STATEMENT

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are subject to the “safe harbor” created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “suggests,” “appears,” “seeks,” “will,” and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients' ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, and our other Securities and Exchange Commission filings made prior to the date hereof.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors' likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to “we”, “us”, “our”, or “Cross Country” in this press release mean Cross Country Healthcare, Inc. and its subsidiaries.


 
Cross Country Healthcare, Inc.
Consolidated Statements of Operations
(Unaudited, amounts in thousands, except per share data)
                   
Three Months Ended Nine Months Ended

September 30,

June 30,

September 30,

2018   2017   2018   2018   2017  
 
Revenue from services $ 200,717 $ 228,488 $ 204,572 $ 615,577 $ 645,374
Operating expenses:
Direct operating expenses 149,155 168,008 150,883 456,573 475,091
Selling, general and administrative expenses 44,086 47,346 45,284 135,004 141,182
Bad debt expense 502 433 611 1,312 1,082
Depreciation and amortization 2,892 2,849 2,963 8,764 7,325
Acquisition-related contingent consideration (a) 16 (605 ) 220 449 (54 )
Acquisition and integration costs (b) 70 1,366 76 261 1,953
Restructuring costs (c) 1,351   724   193   1,979   724  
Total operating expenses 198,072   220,121   200,230   604,342   627,303  
Income from operations 2,645 8,367 4,342 11,235 18,071
Other expenses (income):
Interest expense 1,512 1,221 1,447 4,225 2,975
Gain on derivative liability (d) (1,581 )
Loss on early extinguishment of debt (e) 36 36 4,969
Other income, net (170 ) (57 ) (98 ) (369 ) (116 )
Income before income taxes 1,267 7,203 2,993 7,343 11,824
Income tax expense 1,385   159   1,169   3,717   1,278  
Consolidated net (loss) income (118 ) 7,044 1,824 3,626 10,546
Less: Net income attributable to noncontrolling interest in subsidiary 323   321   285   886   983  
Net (loss) income attributable to common shareholders $ (441 ) $ 6,723   $ 1,539   $ 2,740   $ 9,563  
 
Net (loss) income per share attributable to common shareholders - Basic $ (0.01 ) $ 0.19   $ 0.04   $ 0.08   $ 0.28  
 
Net (loss) income per share attributable to common shareholders - Diluted $ (0.01 ) $ 0.19   $ 0.04   $ 0.08   $ 0.24  
 
Weighted average common shares outstanding:
Basic 35,594   35,748   35,652   35,682   34,768  
Diluted (f) 35,594   36,036   35,832   35,881   36,179  
 

 
Cross Country Healthcare, Inc.
Reconciliation of Non-GAAP Financial Measures
(Unaudited, amounts in thousands, except per share data)
 
    Three Months Ended     Nine Months Ended

September 30,

    June 30,

September 30,

2018       2017   2018   2018       2017  
Adjusted EBITDA: (g)
Net (loss) income attributable to common shareholders $ (441 ) $ 6,723 $ 1,539 $ 2,740 $ 9,563
Interest expense 1,512 1,221 1,447 4,225 2,975
Income tax expense 1,385 159 1,169 3,717 1,278
Depreciation and amortization 2,892 2,849 2,963 8,764 7,325
Acquisition-related contingent consideration (a) 16 (605 ) 220 449 (54 )
Acquisition and integration costs (b) 70 1,366 76 261 1,953
Restructuring costs (c) 1,351 724 193 1,979 724
Gain on derivative liability (d) (1,581 )
Loss on early extinguishment of debt (e) 36 36 4,969
Other income, net (170 ) (57 ) (98 ) (369 ) (116 )
Equity compensation 981 1,068 914 2,364 3,083
Legacy system replacement costs (h) 157 157
Net income attributable to noncontrolling interest in subsidiary 323   321   285   886   983  
Adjusted EBITDA (g) $ 8,112   $ 13,769   $ 8,708   $ 25,209   $ 31,102  
 
Adjusted EPS: (i)
Numerator:
Net (loss) income attributable to common shareholders $ (441 ) $ 6,723 $ 1,539 $ 2,740 $ 9,563
Non-GAAP adjustments - pretax:
Acquisition-related contingent consideration (a) 16 (605 ) 220 449 (54 )
Acquisition and integration costs (b) 70 1,366 76 261 1,953
Restructuring costs (c) 1,351 724 193 1,979 724
Gain on derivative liability (d) (1,581 )
Loss on early extinguishment of debt (e) 36 36 4,969
Legacy system replacement costs (h) 157 157
Nonrecurring income tax adjustments (47 ) (47 )
Tax impact of non-GAAP adjustments (j) (652 )   (198 ) (1,119 )  
Adjusted net (loss) income attributable to common shareholders - non-GAAP $ 537   $ 8,208   $ 1,783   $ 4,456   $ 15,574  
 
Denominator:
Weighted average common shares - basic, GAAP 35,594 35,748 35,652 35,682 34,767
Dilutive impact of share-based payments 131   288   180   199   444  
Adjusted weighted average common shares - diluted, non-GAAP 35,725   36,036   35,832   35,881   35,211  
 
Reconciliation:
Diluted EPS, GAAP $ (0.01 ) $ 0.19 $ 0.04 $ 0.08 $ 0.24
Non-GAAP adjustments - pretax:
Acquisition-related contingent consideration (a) (0.02 ) 0.01 0.01
Acquisition and integration costs (b) 0.04 0.01 0.06
Restructuring costs (c) 0.04 0.02 0.01 0.05 0.02
Gain on derivative liability (d) (0.05 )
Loss on early extinguishment of debt (e) 0.15
Legacy system replacement costs (h) 0.01 0.01
Tax impact of non-GAAP adjustments (j) (0.02 ) (0.01 ) (0.03 )
Adjustment for change in dilutive shares         0.02  
Adjusted EPS, non-GAAP (i) $ 0.02   $ 0.23   $ 0.05   $ 0.13   $ 0.44  
 

 
Cross Country Healthcare, Inc.
Consolidated Balance Sheets
(Unaudited, amounts in thousands)
 
    September 30,     December 31,
2018 2017
 
Assets
Current assets:
Cash and cash equivalents $ 28,065 $ 25,537
Accounts receivable, net 167,200 173,603
Prepaid expenses 5,870 5,287
Insurance recovery receivable 3,287 3,497
Other current assets 1,821 963
Total current assets 206,243 208,887
Property and equipment, net 13,431 14,086
Goodwill, net 117,589 117,589
Trade names, indefinite-lived 26,702 26,702
Other intangible assets, net 55,599 60,976
Non-current deferred tax assets 17,160 20,219
Other non-current assets 20,214 19,228
Total assets $ 456,938 $ 467,687
 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $ 50,268 $ 50,597
Accrued employee compensation and benefits 31,666 34,271
Current portion of long-term debt 7,454 6,875
Other current liabilities 2,567 2,845
Total current liabilities 91,955 94,588
Long-term debt, less current portion 83,132 92,259
Long-term accrued claims 30,566 28,757
Contingent consideration 5,257 5,088
Other long-term liabilities 8,773 9,276
Total liabilities 219,683 229,968
 
Commitments and contingencies
 
Stockholders' equity:
Common stock 4 4
Additional paid-in capital 302,007 305,362
Accumulated other comprehensive loss (1,033) (1,166)
Accumulated deficit (64,371) (67,111)
Total Cross Country Healthcare, Inc. stockholders' equity 236,607 237,089
Noncontrolling interest in subsidiary 648 630
Total stockholders' equity 237,255 237,719
Total liabilities and stockholders' equity $ 456,938 $ 467,687

 
Cross Country Healthcare, Inc.
Segment Data (k)
(Unaudited, amounts in thousands)
 
    Three Months Ended     % Change Fav/(Unfav)
September 30,     % of     September 30,     % of     June 30,     % of Year-over-    
2018 Total 2017 Total 2018 Total Year Sequential
 
Revenue from services:
Nurse and Allied Staffing $ 176,344 88% $ 200,492 88% $ 179,339 88% (12)% (2)%
Physician Staffing 21,158 10% 24,871 11% 21,334 10% (15)% (1)%
Other Human Capital Management Services 3,215 2% 3,125 1% 3,899 2% 3% (18)%
$ 200,717 100% $ 228,488 100% $ 204,572 100% (12)% (2)%
 
Contribution income: (l)
Nurse and Allied Staffing $ 16,534 $ 20,663 $ 16,909 (20)% (2)%
Physician Staffing 1,307 1,340 1,383 (2)% (5)%
Other Human Capital Management Services 70 (1) 312 NM (78)%
17,911 22,002 18,604 (19)% (4)%
 
Unallocated corporate overhead (m) 10,937 9,301 10,810 (18)% (1)%
Depreciation and amortization 2,892 2,849 2,963 (2)% 2%
Acquisition-related contingent consideration (a) 16 (605) 220 (103)% 93%
Acquisition and integration costs (b) 70 1,366 76 95% 8%
Restructuring costs (c) 1,351 724 193 (87)% (600)%
Income from operations $ 2,645 $ 8,367 $ 4,342 (68)% (39)%
 
 
Nine Months Ended

% Change

Fav/(Unfav)

September 30,

% of

September 30,

% of

Year-over-

Year

2018 Total 2017 Total
 
Revenue from services:
Nurse and Allied Staffing $ 540,788 88% $ 564,527 87% (4)%
Physician Staffing 64,052 10% 71,055 11% (10)%
Other Human Capital Management Services 10,737 2% 9,792 2% 10%
$ 615,577 100% $ 645,374 100% (5)%
 
Contribution income: (l)
Nurse and Allied Staffing $ 50,203 $ 54,426 (8)%
Physician Staffing 4,190 4,207 —%
Other Human Capital Management Services 694 (200) 447%
55,087 58,433 (6)%
 
 
Unallocated corporate overhead (m) 32,399 30,414 (7)%
Depreciation and amortization 8,764 7,325 (20)%
Acquisition-related contingent consideration (a) 449 (54) (931)%
Acquisition and integration costs (b) 261 1,953 87%
Restructuring costs (c) 1,979 724 (173)%
Income from operations $ 11,235 $ 18,071 (38)%
 
NM-Not meaningful.
 

 

Cross Country Healthcare, Inc.
Summary Condensed Consolidated Statements of Cash Flows
(Unaudited, amounts in thousands)

 
    Three Months Ended   Nine Months Ended

September 30,

  June 30,

September 30,

2018   2017 2018 2018   2017
 
Net cash provided by operating activities $ 3,818 $ 3,180 $ 4,666 $ 21,757 $ 28,705
Cash used in investing activities

(1,239

)

(86,873

)

(1,287

)

(3,554

)

(90,259

)

Net cash (used in) provided by financing activities

(7,025

)

60,527

(3,418

)

(15,591

)

51,671
Effect of exchange rate changes on cash

(48

)

(5

)

(23

)

(84

)

18
Change in cash and cash equivalents

(4,494

)

(23,171

)

(62

)

2,528

(9,865

)

Cash and cash equivalents at beginning of period 32,559 33,936 32,621 25,537 20,630
Cash and cash equivalents at end of period $ 28,065 $ 10,765 $ 32,559 $ 28,065 $ 10,765
 
 
 

Cross Country Healthcare, Inc.
Other Financial Data
(Unaudited)

 
Three Months Ended Nine Months Ended

September 30,

June 30,

September 30,

2018 2017 2018 2018 2017
 
Consolidated gross profit margin (n) 25.7% 26.5% 26.2% 25.8% 26.4%
 

Nurse and Allied Staffing statistical data:

FTEs (o) 6,953 7,706 7,143 7,187 7,355
Average Nurse and Allied Staffing revenue per FTE per day (p) $ 276 $ 283 $ 276 $ 276 $ 281
 

Physician Staffing statistical data:

Days filled (q) 13,375 15,567 13,751 41,611 45,823
Revenue per day filled (r) $ 1,582 $ 1,598 $ 1,551 $ 1,539 $ 1,551
 

 
(a)   Acquisition-related contingent consideration represents the fair value and accretion adjustments to the contingent consideration liabilities for the Mediscan acquisition that closed on October 30, 2015 and the US Resources Healthcare acquisition that closed on December 1, 2016.
(b) Acquisition and integration costs are primarily related to the Advantage RN, LLC acquisition that closed effective July 1, 2017.
(c) Restructuring costs related to severance and lease consolidations incurred as part of separate and discrete cost savings initiatives.
(d) Gain on derivative liability for the nine months ended September 30, 2017 represents the change in the fair value of embedded features of the Convertible Notes.
(e) Loss on early extinguishment of debt for the three and nine months ended September 30, 2018 is related to an early payment of $5.0 million made in the third quarter on the Company's term loans. For the nine months ended September 30, 2017, the loss on early extinguishment of debt is related to the Company's settlement of its Convertible Notes on March 17, 2017.
(f) Due to the net loss for the three months ended September 30, 2018, 130,965 shares were excluded from diluted weighted average shares. When applying the if-converted method to our Convertible Notes, 967,342 shares were included in diluted weighted average shares for the nine months ended September 30, 2017.
(g) Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as net income attributable to common shareholders before interest expense, income tax expense, depreciation and amortization, acquisition-related contingent consideration, acquisition and integration costs, restructuring costs, gain on derivative liability, loss on early extinguishment of debt, other income, net, equity compensation, legacy system replacement costs, and includes net income attributable to noncontrolling interest in subsidiary. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common shareholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company's credit facilities in calculating various ratios. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.
(h) Legacy system replacement costs for the three and nine months ended September 30, 2018 are related to the Company's project to replace its legacy system supporting its travel nurse staffing business. These costs are reported in selling, general, and administrative expenses on the consolidated statement of operations and included in unallocated corporate overhead in segment data.
(i) Adjusted EPS, a non-GAAP financial measure, is defined as net income attributable to common shareholders per diluted share before the diluted EPS impact of acquisition-related contingent consideration, acquisition and integration costs, restructuring costs, gain on derivative liability, loss on early extinguishment of debt, legacy system replacement costs, and nonrecurring income tax adjustments. Adjusted EPS should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes it provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company.
(j) Due to the Company previously maintaining a full valuation allowance, there was no tax impact on non-GAAP measures in the three and nine months ended September 30, 2017.
(k) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC.
(l) Contribution income is defined as income from operations before depreciation and amortization, acquisition-related contingent consideration, acquisition and integration costs, restructuring costs, core system replacement costs, and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance.
(m) Unallocated corporate overhead includes corporate compensation and benefits, and general and administrative expenses including rent and utilities, computer supplies and expenses, insurance, professional expenses, corporate-wide projects (initiatives), and public company expense.
(n) Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.
(o) FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.
(p) Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue per FTE by the number of days worked in the respective periods. Nurse and Allied Staffing revenue also includes revenue from the permanent placement of nurses.
(q) Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours. Prior periods have been recalculated to include the impact of the accrued revenue.
(r) Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented. Prior periods have been recalculated to include the impact of the accrued revenue and days.
 

CONTACT:
Cross Country Healthcare, Inc.
William J. Grubbs, 561-237-6202
President & Chief Executive Officer
wgrubbs@crosscountry.com